Evidence map›Paper›PMID 10850854›Full record

ArticleInflammation2000

Effects of several glucocorticosteroids and PDE4 inhibitors on increases in total lung eosinophil peroxidase (EPO) levels following either systemic or intratracheal administration in sephadex- or ovalbumin-induced inflammatory models.

D M Hammerbeck, S M McGurran, P L Radziszewski, E A Egging, D D Johnson, A M Hupperts, G W Gullikson

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

D M Hammerbeck3M Pharmaceuticals, 3M Company, St. Paul, Minnesota 55144, USA.
S M McGurran
P L Radziszewski
E A Egging
D D Johnson
A M Hupperts
G W Gullikson
3M (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Representative glucocorticosteroids (GCS) and phosphodiesterase IV (PDE4) inhibitors were compared in several models of pulmonary inflammation ranging in severity. Lung tissue eosinophil peroxidase (EPO) levels rather than bronchoalveolar lavage fluid (BALF) EPO or eosinophil percentages were used to indicate eosinophil recruitment after intratracheal instillation of sephadex beads in rats or nebulized ovalbumin in sensitized guinea pigs. A single oral or intratracheal administration of a GCS was effective against mild and robust sephadex-induced eosinophilia whereas the PDE4 inhibitors evaluated appeared more effective in the milder sephadex models. The GCS were also more effective against sephadex-induced than ovalbumin-induced eosinophilia. The effectiveness of the GCS and PDE4 inhibitors improved when the severity of the ovalbumin-induced eosinophilia was decreased. Multiple day dosing also improved activity. These studies indicated that activity was influenced greatly by administration protocols, the severity of the inflammatory response and possibly the method used for estimating eosinophil recruitment.

Indexed as

3',5'-Cyclic-AMP PhosphodiesterasesAndrostadienesAnimalsAsthmaBeclomethasoneBenzamidesBudesonideCyclic Nucleotide Phosphodiesterases, Type 4DexamethasoneDextransDisease Models, AnimalEnzyme InhibitorsEosinophil PeroxidaseEosinophilsFluticasoneGlucocorticoids3',5'-Cyclic-AMP PhosphodiesterasesAndrostadienesBeclomethasoneBenzamidesBudesonideCDP 840Cyclic Nucleotide Phosphodiesterases, Type 4DexamethasoneDextransEnzyme InhibitorsEosinophil PeroxidaseFluticasoneGlucocorticoidsOvalbuminPeroxidasespiclamilastPyridinesRolipramsephadex

Identifiers

PMID10850854
OpenAlexW240613836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.